WGSWW — GeneDx Holdings Corp.
NASDAQ
GeneDx Holdings Corp. (WGSWW) common stock listed on NASDAQ. It is led by Katherine A. Stueland, based in North Tower, Stamford, CT, United States, 06902, with about 1,300 employees. GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Latest reported WGSWW revenue for 2025-09-30 was $116.7M. Net income was -$7.6M. Revenue was up 13.7% from 2025-06-30 to 2025-09-30.
Use this WGSWW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the WGSWW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the WGSWW SEC filings page. Lician reads the product cache first so this HTML stays unique to GeneDx Holdings Corp. even when a live quote feed is slow.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
WGSWW Key Statistics
EPS
-$1.94
Revenue
$305.45M
Net Income
-$52.29M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+50.8%
Profit Margin
-17.1%
Employees
1,300
WGSWW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $305.45M | $202.57M | $234.69M | $57.80M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$52.29M | -$175.77M | -$548.98M | -$40.19M |
| EPS (Diluted) | -$1.94 | -$7.23 | -$53.63 | -$2.27 |
Total Assets
$419.38M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$85.21M
Operating Cash Flow
-$28.50M
Free Cash Flow
$0.00
GeneDx Holdings Corp. Company Information
- President, CEO & Director
- Katherine A. Stueland
- Headquarters
- North Tower, Stamford, CT, United States, 06902
- Website
- www.genedx.com
- Phone
- 888 729 1206
- IPO / Founded
- 2020-10-29